Glucotrack stockholders approve Nasdaq-required share issuances at special meeting

Glucotrack, Inc. held a special meeting of stockholders on September 11, 2026, where investors voted on proposals tied to prior financing agreements, according to an 8-K filed with the SEC. On the record date, there were 10,578,822 shares of Common Stock outstanding, and 3,661,960 votes, or approximately 34.61% of the total, were represented at the meeting in person or by proxy, constituting a quorum.¹

The first proposal concerned the full issuance of shares of Common Stock, including the shares issuable under the ELOC Purchase Agreement, the commitment shares issuable thereunder, and the shares issuable upon exercise of the commitment warrant issued in connection therewith, to White Lion Capital, LLC¹, for purposes of complying with Nasdaq Listing Rule 5635(d). The vote tally was 3,101,374 for, 228,374 against, and 332,212 abstaining.¹

The second proposal addressed the full issuance of shares of Common Stock issuable upon conversion of the Bridge Notes and exercise of the Bridge Warrants issued to the Bridge Investors pursuant to the Purchase Agreement¹. That proposal passed 3,106,894 for, 226,850 against, and 328,216 abstaining.¹

Because both measures passed, a third proposal to adjourn the meeting, which would have applied only if more time was needed to pass Proposals 1 or 2, was not presented to stockholders.¹

Separately, the filing notes that on September 14, 2026, the Company and the PIPE Purchaser entered into an amendment to the Common Warrants to provide that the holder shall not be entitled to exercise a Common Warrant, in whole or in part, and the Company shall not effect any exercise of a Common Warrant or issue any shares pursuant thereto, unless and until the Company has obtained the approval of its stockholders for the issuance of all shares issuable pursuant to the Common Warrants in accordance with Nasdaq Listing Rule 5635(d) and any other applicable rules of The Nasdaq Stock Market LLC.¹